Your browser doesn't support javascript.
loading
Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer.
Palomero, Jara; Panisello, Carla; Lozano-Rabella, Maria; Tirtakasuma, Ricky; Díaz-Gómez, Judit; Grases, Daniela; Pasamar, Helena; Arregui, Laura; Dorca Duch, Eduard; Guerra Fernández, Esther; Vivancos, Ana; de Andrea, Carlos E; Melero, Ignacio; Ponce, Jordi; Vidal, August; Piulats, Josep Maria; Matias-Guiu, Xavier; Gros, Alena.
Afiliación
  • Palomero J; Tumor Immunology and Immunotherapy, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Panisello C; Tumor Immunology and Immunotherapy, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Lozano-Rabella M; Tumor Immunology and Immunotherapy, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Tirtakasuma R; Tumor Immunology and Immunotherapy, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Díaz-Gómez J; Tumor Immunology and Immunotherapy, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Grases D; Tumor Immunology and Immunotherapy, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Pasamar H; Tumor Immunology and Immunotherapy, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Arregui L; HUB-ICO-IDIBELL Biobank, Bellvitge Institute for Biomedical Research, L'Hospitalet de Llobregat, Spain.
  • Dorca Duch E; Pathology, Bellvitge University Hospital, IDIBELL, L'Hospitalet de Llobregat, Spain.
  • Guerra Fernández E; Pathology, Bellvitge University Hospital, IDIBELL, L'Hospitalet de Llobregat, Spain.
  • Vivancos A; Cancer Genomics, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • de Andrea CE; Pathology, Clinica Universidad de Navarra, Pamplona, Spain.
  • Melero I; Centro de Investigación Biomedica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Ponce J; Centro de Investigación Biomedica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Vidal A; Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Pamplona, Spain.
  • Piulats JM; Navarra Institute for Health Research IDISNA, Pamplona, Spain.
  • Matias-Guiu X; Department of Gynaecology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Spain.
  • Gros A; Pathology, Bellvitge University Hospital, IDIBELL, L'Hospitalet de Llobregat, Spain.
J Immunother Cancer ; 10(12)2022 12.
Article en En | MEDLINE | ID: mdl-36581331
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Linfocitos Infiltrantes de Tumor / Neoplasias Endometriales Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Immunother Cancer Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Linfocitos Infiltrantes de Tumor / Neoplasias Endometriales Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Immunother Cancer Año: 2022 Tipo del documento: Article